We have an emerging new entrant in the increasingly crowded weight loss drug space.

Recursion Pharmaceuticals (NASDAQ: RXRX) was in the headlines on Monday, and for the right reason. One of the biotech company's investigational drugs did well in a clinical trial, and investors ...

The ASH meeting included positive early results about a Terns drug for chronic myeloid leukemia and a Kura menin-blocker for ...

Two oral presentations showcase robust efficacy and durable responsesBOSTON, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Imviva Biotech, a clinical-stage biotechnology company developing next-generation ...

NDAA package revives stalled measures on US outbound investment and biotech, signalling Capitol Hill’s hardened stance ...

Data from Structure Therapeutics and WAVE Life Sciences show that threats to Eli Lilly and Novo Nordisk’s dominance in weight ...

Precise Bio Inc., a Greensboro-based clinical-stage regenerative medicine company, has announced the world’s first transplant ...

As of Monday, December 08, Legend Biotech Corporation’s LEGN share price has dipped by 8.82%, which has investors questioning if this is right time to buy.

The CEO foresees a "snowball effect" of life sciences companies coming to Dallas, but a couple things need to happen first.

Provost Ibba described Chapman as a community defined by its willingness to come together across disciplines, whether in the ...

With the best-selling medication in the world, tirzepatide, and a record-setting $1 trillion valuation to go with it, Eli ...

Evaxion Biotech AS (NASDAQ:EVAX) climbed 4.2% in Monday’s premarket session after sharing new preclinical data supporting its ...